A repurposing label pathway with short exclusivity that non-profits can hold
Create a way for a charity or university to get a cheap old drug officially approved for a new cancer use, with a few years of protection on that use so trial costs can be recovered without high prices.
A dedicated regulatory pathway for new oncology indications of off-patent drugs, accessible to non-commercial sponsors, with three to five years of indication-specific data exclusivity that can be assigned to a non-profit or public body. The exclusivity is for reimbursement of the indication rather than for the molecule, so generic supply for existing uses is unaffected; a modest per-indication payment from payers repays the trial. Without this, academic repurposing results cannot reach the label and remain off-label and unevenly used.
- Incentives reward me-too drugs and marginal gains · The system pays the same for a drug that adds two months as for a cure, so companies race to copy rather than to cure.
- No incentive to repurpose cheap drugs · Old, cheap drugs with anti-cancer signals never get the trials they need because no one profits from the result.
Pages like this
not linked directly; found by shared links- IdeaA public registry of stalled academic assets and shelved company compounds
Shares Automatic offer of shelved cancer assets to non-profits after two years, A non-profit pharmaceutical company for the cancers markets ignore.
- IdeaThree years of indication-specific exclusivity for proving a new cancer use of an old drug
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
- IdeaPayers pre-commit to cover off-label generics when a definitive trial is positive
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
- IdeaA $50 million prize for the first off-patent drug proven to extend cancer survival
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
- IdeaA public fund and label pathway to trial generic drugs against cancer
Shares No incentive to repurpose cheap drugs, Incentives reward me-too drugs and marginal gains.
- IdeaAdvance market commitments for paediatric and rare cancer drugs
Shares A non-profit pharmaceutical company for the cancers markets ignore, Incentives reward me-too drugs and marginal gains.